Table 1.
Transplant related outcomes in patients who received Gemcitabine plus Cisplatin as neo-adjuvant treatment for cholangiocarcinoma prior to liver transplantation.
| Patients ID | Sex | Native Liver Diagnosis | Treatment | Treatment Duration- Days | Days to Transplant | Recurrence or Rejection | Days to The Date of Recurrence or Rejection | Days to The Last Follow up | Days to Death |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Female | Hilar CCA | Gem/Cis | 603 | 8 | no | 813 | ||
| 2 | Male | CCA | Gem/Cis | 149 | 5 | Yes | 603 | 871 | 885 |
| 3 | Male | CCA | Gem/Cis | 250 | 20 | no | 824 | ||
| 4 | Male | CCA | Gem/Cis | 120 | 369 | no | 967 | ||
| 5 | Male | CCA | Gem/Cis | 83 | 472 | no | 1405 | ||
| 6 | Male | Hilar CCA | Gem/Cis | 161 | 64 | no | 418 | ||
| 7 | Male | Hilar CCA | Gem/Cis | 201 | 5 | no | 812 | ||
| 8 | Male | CCA | Gem/Cis | 206 | 79 | no | 831 | ||
| 9 | Male | IHCCA | Gem/Cis | 77 | 445 | no | 1834 | ||
| 10 | Female | IHCCA | Gem/Cis | 200 | 113 | no | 870 |